MAIC: Efficacy of Zanubrutinib versus Acalabrutinib in R/R CLL

Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Matching Adjusted Indirect Comparison (MAIC) methodology. In this video, we explore the use of MAIC for comparing the efficacy of zanubrutinib vs. acalabrutinib, using patient level data from the ALPINE trial and published data from the ASCEND trial, respectively. Our results emphasize a few methodological aspects of MAICs, such as the parameters matched in the analysis, the effective sample size, importance of sensitivity analysis, data cut-offs used and the impact of COVID-19 where relevant. Perfect for those keen on advanced healthcare research.